Тәуекелге әсер ететін фактор
Табыстылыққа әсер ететін фактор
Гуру портфелінде
Басқарушы | Қор | Үлес | Үлестің өзгеруі |
|---|---|---|---|
| Стив Коэн | Point72 Asset Management | 0.0% | -0.02% |
| Кен Гриффин | Citadel Advisors LLC | 0.0% | -0.01% |
Компания туралы
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.